Status:
COMPLETED
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Advanced Breast Cancer
Antibiotic
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
This is a phase II,single center,prospective, single arm clinical trial. The objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in Advanced Breast Cancer whose evalu...
Detailed Description
This is a phase II,single center,prospective, single arm clinical trial. A lot of in vitro and in vivo study demonstrate that quinolones antibiotics can increase anti-tumor effect. The objective is to...
Eligibility Criteria
Inclusion
- Female ≥ 18 years, ≤70 years.
- Has measurable metastatic MBC, with at least 1 measurable lesion per RECIST criteria.
- Fail first-line or above anti-tumor treatment
- Evaluation is stable disease with a trend of progression.
- Minimum life expectancy 16 weeks
- Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis
- ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks
- Normal organ function.
- Has signed a Patient Informed Consent Form
Exclusion
- Hypersensitivity to moxifloxacin or other quinolones.
- Tendon damage,peripheral neuropathy,myasthenia gravis.
- Rapidly progressive visceral disease not suitable for further therapy.
- Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV
- With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment
- Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent
- Inability or unwillingness to comply with study procedures, including inability to take regular oral medication
- Researchers consider it is not suitable for participation.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2018
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03405168
Start Date
January 1 2018
End Date
July 30 2018
Last Update
November 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongyu Yuan
Guangzhou, Guangdong, China, 510000